Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stada-Mabxience Bevacizumab Is Latest To Receive EU Nod

As Riemser’s Thiotepa And Teva Inhalers Also Endorsed By CHMP

Executive Summary

Stada and Mabxience have received an endorsement from the EMA for their partnered bevacizumab biosimilar rival to Avastin. Meanwhile, Riemser’s thiotepa generic and two Teva inhalers have also received positive opinions from the CHMP.

You may also be interested in...



MS Pharma Partners With Mabxience For Bevacizumab In MENA Region

Jordan-based MS Pharma has struck a deal with Insud Pharma subsidiary Mabxience to commercialize its bevacizumab biosimilar in the Middle East and North Africa region. The move comes after Mabxience partnered with Zentiva to commercialize bevacizumab in 21 European countries. Meanwhile, MS Pharma has also partnered with Alvion Pharma for rosuvastatin/ezetimibe in the MENA region.

Mabxience Allies With Zentiva For European Bevacizumab Launch

Mabxience and Zentiva have partnered to launch the Alymsys bevacizumab biosimilar rival to Avastin that recently received a pan-European marketing authorization.

Stada Launches Bevacizumab Biosimilar In EU

Stada has launched its Oyavas version of bevacizumab upon EU approval, initially rolling out the oncology biosimilar in Germany and the Netherlands with other countries to follow.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150629

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel